We Care | Quercis Pharma

QUERCIS

ABOUT

TEAM

SCIENCE

HIGHLIGHTS

PUBLICATIONS

EXPANDED ACCESS

NEWS

CONTACT

QUERCIS

We Care

Thank you for visiting us from the Prix Galien USA community. Here is a look at our recent recognition and the clinical milestones ahead.

Recent Updates

Nominated for the 2026 Prix Galien USA Award – Best Startup

Nominated for 2025 Galien Award – Best Startup

Recognized as a Top 10 Drug Discovery & Development Solutions Provider in Europe (Life Sciences Review, 2023)

CEO Thomas Lines featured in The Silicon Review for leadership in global health innovation

Upcoming

Phase III trial for Kinisoquin™ in cancer-associated thrombosis (CAT) ongoing under FDA Special Protocol Agreement; interim data expected Q2 2027

Phase III in Sickle Cell Disease (SCD); steady-state data expected Q4 2026

Phase II trial with Administration for Strategic Preparedness and Response (ASPR)

Explore Quercis

EXPLORE OUR SCIENCE

MEET THE TEAM

QUERCIS

Heal the world

™

Kinisoquin™ is an investigational therapy in clinical development. It has not been approved for use by any regulatory authority.

QUERCIS

Heal the world

™

Kinisoquin™ is an investigational therapy in clinical development. It has not been approved for use by any regulatory authority.

QUERCIS

Heal the world

™

Kinisoquin™ is an investigational therapy in clinical development. It has not been approved for use by any regulatory authority.